Table 3.
Rate of CHC nodules characterized as malignant and at risk for misdiagnosis for HCC according to the different contrast enhanced techniques.
| CEUS (n = 27) | CT (n = 34) | MRI (n = 17) | p values | |
|---|---|---|---|---|
| CHC nodules characterized as malignant (classical definition) (%) | 21 (78%) | 7 (24%) | 5 (29%) | *p < 0.001, **p = 0.004 ***p = ns |
| CHC nodules at risk for misdiagnosis for HCC (classical definition) (%) | 13 (48%) | 5 (15%) | 3 (18%) | *p = 0.001, **p = 0.057, ***p = ns |
| CHC nodules characterized as malignant (classified as LI-RADS LR-5 or LR-M) (%) | 21 (78%) | 22 (65%) | 9 (53%) | *p = ns, **p = ns, ***p = ns |
| CHC nodules at risk for misdiagnosis for HCC (classified as LI-RADS LR-5) (%) | 14 (52%) | 4 (11%) | 3 (18%) | *p = 0.001, **p = 0.030, ***p = ns |
*CEUS vs CT; **CEUS vs MRI; ***CT versus MRI.
CEUS: contrast-enhanced ultrasound; CHC: combined hepatocellular–cholangiocellular carcinoma; CT: computed tomography; HCC: hepatocellular carcinoma; MRI: magnetic resonance imaging; LI-RADS: Liver Imaging Reporting and Data System.